ARCHIVES

Amgen Claimed QOL Benefit Despite FDA Label Change.

This article is from The Cancer Letter archive.

Vol. 33 No. 19 | May 18, 2007

Download PDF Visit The Full Archive

Related Articles

In Brief: Pay raise Must Come From Intramural Funds, Not Extramural, Administration Says

May 9, 1980

Nine contracts For Automated Pap Test Systems Total $1.7 Million

October 18, 1974

BioSeek Awarded NIH SBIR For Compound Validation.

July 4, 2003

Phase III Trial In Recurrent Disease Shows Lower Risk of Progression or Death by 34%

June 28, 2013

SWOG Study To Test Predictive Value Of Circulating Tumor Cells In Breast Cancer

October 27, 2006

House subcommittee proposes 2.8 percent increase for NIH, NCI.

July 16, 2004